ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Infectious Diseases
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1619997
Synthetic Bakuchiol Derivatives: Ester and Ether Analogues with Activity Against Clinically Important Bacteria
Provisionally accepted- 1Departamento de Ciencias Geográficas, Facultad de Ciencias Naturales y Exactas, Universidad de Playa Ancha, Valparaiso, Chile
- 2Department of Chemistry, Universida Tecnico Federico Santa Maria, valparaiso, Chile
- 3Millennium Nucleus Bioproducts, Genomics and Environmental Microbiology (BioGEM), Center of Interdisciplinary Biomedical and Engineering Research for Health (MEDING), Viña del mar, Chile
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: With the rise of antibiotic resistance and healthcare-associated infections, there is a growing need for alternative therapies. Otholobium glandulosum (L.) J.W. Grimes (= Psoralea glandulosa L.) (Fabaceae) and its active compound bakuchiol have demonstrated significant antimicrobial and biological potential. This study investigates bakuchiol-based synthetic derivatives as promising antibacterial agents against clinically relevant pathogens. Methods: From the aerial parts of O. glandulosum, a resinous exudate was obtained, from which bakuchiol was isolated. This compound was used as a precursor to synthesize a series of ester-type (4-8) and ether-type (9-15) derivatives. All compounds were purified, their structures were confirmed by nuclear magnetic resonance (NMR), and they were evaluated in vitro for antibacterial activity against Gram-positive and Gram-negative strains. The most active derivatives were further tested in Live/Dead assays, and their pharmacokinetic and toxicity profiles were predicted in silico using the SwissADME and ADMETlab servers. Results: The ester derivatives exhibited bactericidal activity against Staphylococcus aureus and Streptococcus agalactiae, with compounds 4 and 5 being particularly effective, causing 90% growth inhibition. Compound 6 displayed a MIC of 320 µg/mL for Pseudomonas aeruginosa. However, none of the compounds showed bactericidal activity against Escherichia coli. Structure-activity relationship (SAR) analysis indicated that chain length, lipophilicity, and stereochemistry influenced both efficacy and bacterial selectivity. In silico assays indicated acceptable absorption, low mutagenicity, moderate hepatotoxicity, and limitations related to high LogP values. Conclusion: These results support the potential of bakuchiol ester-type derivatives as antibacterial agents, which encourages future in vivo studies and synthetic optimization.
Keywords: Otholobium glandulosum, Bakuchiol, bakuchiol derivatives, Antibacterial activity, Clinical bacteria
Received: 02 May 2025; Accepted: 02 Oct 2025.
Copyright: © 2025 Valdés Navarro, Muñoz, Martinez-Lobos, Ferreria, Silva, Madrid, Díaz, Villarroel and Montenegro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Alejandro Madrid, alejandro.madrid@upla.cl
Iván J. Montenegro, ivan.montenegro@uv.cl
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.